Document is current
Any future updates will be listed below
-
Authors
Cao, Yunlong https://orcid.org/0000-0001-5918-1078
Wang, Jing https://orcid.org/0000-0002-9084-9985
Jian, Fanchong https://orcid.org/0000-0001-8703-3507
Xiao, Tianhe
Song, Weiliang
Yisimayi, Ayijiang
Huang, Weijin https://orcid.org/0000-0002-4246-8889
Li, Qianqian
Wang, Peng
An, Ran
Wang, Jing
Wang, Yao
Niu, Xiao
Yang, Sijie
Liang, Hui
Sun, Haiyan
Li, Tao
Yu, Yuanling
Cui, Qianqian
Liu, Shuo
Yang, Xiaodong
Du, Shuo https://orcid.org/0000-0003-0936-0785
Zhang, Zhiying https://orcid.org/0000-0002-5690-9796
Hao, Xiaohua
Shao, Fei
Jin, Ronghua
Wang, Xiangxi
Xiao, Junyu https://orcid.org/0000-0003-1822-1701
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Xie, Xiaoliang Sunney https://orcid.org/0000-0001-9281-5239
- License Information
-
More Information
Article History
Received: 7 December 2021
Accepted: 23 December 2021
First Online: 23 December 2021
Competing interests
: X.S.X. and Y.C. are listed as inventors on a patent related to BD series antibodies and DXP-604 (PCT/CN2021/093305) under Peking University. X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. The remaining authors declare no competing interests.
